EGFR and colorectal cancer: The development of targeted therapies, including anti-EGFR monoclonal antibodies (such as panitumumab and cetuximab), has been beneficial to colorectal cancer patients, and these therapies are becoming standards for treatment of metastatic colorectal cancer.